TROV vs. CVM, ZIVO, IZTC, CRTX, JATT, FNCH, ALVR, AIM, NKGN, and CLDI
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include CEL-SCI (CVM), ZIVO Bioscience (ZIVO), Invizyne Technologies (IZTC), Cortexyme (CRTX), JATT Acquisition (JATT), Finch Therapeutics Group (FNCH), AlloVir (ALVR), AIM ImmunoTech (AIM), NKGen Biotech (NKGN), and Calidi Biotherapeutics (CLDI). These companies are all part of the "medical" sector.
Cardiff Oncology vs. Its Competitors
CEL-SCI (NYSE:CVM) and Cardiff Oncology (NASDAQ:TROV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.
Cardiff Oncology has higher revenue and earnings than CEL-SCI. CEL-SCI is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
CEL-SCI has a net margin of 0.00% compared to Cardiff Oncology's net margin of -3,688.31%. Cardiff Oncology's return on equity of -202.00% beat CEL-SCI's return on equity.
12.1% of CEL-SCI shares are held by institutional investors. Comparatively, 10.0% of Cardiff Oncology shares are held by institutional investors. 9.9% of CEL-SCI shares are held by insiders. Comparatively, 0.6% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
CEL-SCI has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
In the previous week, CEL-SCI had 4 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for CEL-SCI and 0 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.00 beat CEL-SCI's score of -0.17 indicating that Cardiff Oncology is being referred to more favorably in the news media.
Summary
Cardiff Oncology beats CEL-SCI on 7 of the 12 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TROV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:TROV) was last updated on 9/4/2025 by MarketBeat.com Staff
Free TROV Stock Alerts